Tuesday, 17 June 2014

According to a new market report published by Transparency Market Research  "Neuromodulation Devices Market - Global Industry Analysis, Size, Share and Forecast, 2012 - 2018 " the global neuromodulation devices market was valued at USD 2,758 million in 2011 and is expected to grow at a CAGR of 14.4% from 2012 to 2018, to reach an estimated value of USD 7,072.6 million by 2018.

Browse the  Neuromodulation Devices Market report with full TOC at http://www.transparencymarketresearch.com/global-neuromodulation-devices-market.html

The market is driven by factors such as the aging world population leading to chronic diseases such as Parkinson´s and Alzheimer´s disorders and technological advancements in the field of neuromodulation devices including the invention of transversal neuromodulation technology by NMT (Neurowave Medical Technologies). Moreover, the rising prevalence of chronic diseases, increasing demand for minimally invasive surgeries, the availability of external funding to conduct clinical studies to help come up with new and technologically advanced products and the rising healthcare related consumer expenditure have also driven the growth in this market. The fact that a neuromodulation device could be used as an add-on treatment and so can be used simultaneously with other medications also drives the market forward.


The North American region holds majority of the market share and accounted for a share of 65% in 2011. The North American neuromodulation device market was valued at USD 1,792.7 million in 2011. The economic developments in the Asia Pacific region make it the fastest growing region (CAGR of more than 15% from 2012 to 2018) in the neuromodulation devices market.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

The future growth of the market will be ensured by capitalizing on market opportunities such as increasing healthcare related consumer expenditure in emerging economies in the Asia Pacific, Latin American and Eastern European regions. The availability of medical device manufacturing outsourcing options helps in curbing costs and thereby enhances profit margins. Also, the presence of consolidation options in the healthcare industry helps in strengthening the revenue base to conduct R&D exercises for new product development and thus helps in strengthening market share.

Monday, 16 June 2014

According to a new market report published by Transparency Market Research "Nutraceutical Ingredients Market - Global Industry Analysis, Market Size, Share, Growth And Forecast 2007 - 2017", global nutraceutical ingredients market is expected to be worth USD 20.8 billion in 2012 and is further expected to reach USD 29.5 billion in 2017, growing at a CAGR of 7.3% from 2012 to 2017. The body building segment is expected to be the largest segment at USD 9.5 billion in 2012. In the overall global market, Asia Pacific region is expected to maintain its lead position in terms of revenue till 2017. Asia Pacific is expected to enjoy 37.5% of global nutraceutical ingredients market revenue share in 2017 followed by North America.

Browse the Nutraceutical Ingredients Market report with full TOC athttp://www.transparencymarketresearch.com/nutraceutical-ingredients-market.html

Increasing number of clinical studies confirming the health benefits of nutraceuticals and their broad applications in food, beverages, dietary supplements, and pediatric and adult nutritional preparations has provided support for the growing use of nutraceutical ingredients. Moreover, faster growth in consumption of nutraceutical ingredients worldwide, especially in developing economies has boosted the growth of nutraceutical ingredient market. In addition, increasing economic prosperity in developing countries including India, China, Brazil, Mexico, Russia,South Africa, South Koreaand Poland will enable consumers to spend more on health and nutrition. This will boost the future growth of the nutraceutical ingredient market.


Major segments of nutraceutical ingredients market include Body building, weight control, diabetes control and pain relief. In 2011, body building was the largest segment followed by weight control. The controlling diabetes segment was the third largest segment, accounting for 16.5% revenue share in 2011.
Amino acids and soy-based ingredients segments of body building market witnessed healthy growth rate during the review period (from 2007 to 2011). The growth in amino acid & soy-based ingredient segment is largely attributed to increased trend of fitness in most of the developing nations. The protein and peptide segment is also expected to have steady growth rate because of growing demand for nutritional diet and proper physic all over the world.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Nutraceutical ingredients presents opportunity for new entrants as well for existing players, due to the fact that most of the raw materials are abundant and product manufacturers are increasingly focusing on contract manufacturing outsourcing (CMO). Moreover, large product manufacturers are looking for backward integration, which will grow the competition into the market and will intern increase the market size of the nutraceutical ingredients.
This report is an effort to identify factors, which will be the driving force behind the nutraceutical ingredient market and its sub-markets over the next six years. The report provides extensive analysis of the nutraceutical industry, current market trends for better understanding of the nutraceutical ingredient market.

According to a new market report published by Transparency Market Research, "Enteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global enteric disease testing market was valued at USD 3.1 billion in 2012 and is expected to grow at a CAGR of 2.4% from 2013 to 2019, to reach an estimated value of USD 3.6 billion in 2019.


Enteric diseases are major causes of morbidity and mortality worldwide. Developing socio-economic countries with poor drainage, sanitation along with overcrowding and low hygiene awareness account for majority of enteric infection incidences prevailing worldwide. These diseases usually exhibit mild symptoms but if not treated on time can lead to severe complications, resulting in death. In order to manage these diseases effectively, their early detection is essential. Various enteric diseases responsible for diarrhea, stomach pain, nausea, vomiting, anorexia, weight loss and fever are amebiasis, giardiasis, rotavirus infection, salmonellosis and shigellosis.


Traditionally, diagnosis of enteric infections relied on culture results of fecal specimen. Today, the world is witnessing a paradigm shift from culture to EIA (enzyme immunoassaya) and PCR (polymerase chain reaction) based tests owing to advantages associated with these newer testing methods. EIA and PCR tests offer enhanced sensitivity and specificity compared to culture tests and also give quick results. Globally the market for enteric disease testing is growing at a CAGR of 2.4% under the influence of rising awareness, demand for point of care testing and increasing application of molecular diagnostics. Use of molecular diagnostic products has made diagnosis easy and possible, even those strains which once seemed to be difficult and impossible. North America and Europe represent the largest regional markets because of rapid demand for molecular based diagnostics and due to high level of awareness among people about the diseases. C.difficile infection is one of the major causes of antibiotic related diarrhea in developed regions.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

Various epidemiological sources including CDC and American Association for Clinical Chemistry suggest that C.difficile infection incidence per 100,000 people has increased over the past few decades in United States. In developing nations, frequent travelling to regions where enteric diseases are epidemic is also one of the reasons driving the market growth. Asia-Pacific and Africa have been predicted to grow rapidly during the forecast period. In developing nations of Asia-pacific, Africa and Latin America, the market is also growing due to advent of rapid dipstick tests which can be applied by the patient themself. These regions associated with inadequate healthcare infrastructure do not possess substantial number of laboratories to perform laboratory based tests. Thus, rapid dipstick test kits being inexpensive and easy to use are widely accepted in these regions for managing enteric illness. Continuously improving economy and rising healthcare expenditure in these regions are also anticipated to drive the market. The market is also growing due to emergence of new strains; sources from Eurosurveillance suggest that the norovirus infection is increasing worldwide, including United Kingdom, the Netherlands, France, Japan and Australia due to emergence of new strain of genotype II.4 (GII.4) that is also known as Sydney strain.

According to a new market report published by Transparency Market Research "Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

Browse the Pain Management Therapeutics Market Research report with full TOC at http://www.transparencymarketresearch.com/pain-management-therapeutics.html

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.
Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.


The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period.

Browse all Pharmaceutical Market Research Reports @http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.
The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.

Friday, 13 June 2014

According to the latest market report published by Transparency Market Research "Liver Diseases Therapeutics Market (Chemotherapy, Anti-Virals, Vaccines, Targeted Therapy and Immunosuppressants) - Global Industry Analysis, Size, Share, Trends and Forecast, 2012 - 2018", the global liver diseases therapeutics market was worth USD 6.5 billion in 2011 and is expected to reach USD 10.9 billion in 2018, growing at a CAGR of 8.6% from 2012 to 2018. In the overall global market, anti-viral drugs are expected to create its lead position in terms of revenue generation by 2018. Anti-viral drugs will have a share of 32.7% of the global market followed by vaccines at 19.1% in 2018.

Browse the Liver Diseases Therapeutics Market full report at http://www.transparencymarketresearch.com/liver-diseases-therapeutics.html 

The major drivers of the global liver disease therapeutics market are increasing aging population inducing chronic diseases such as hepatitis and liver cancer, increasing global prevalence of liver disorder, high unmet needs existing in liver cancer and increased vaccination in emerging economies. However side-effects and risks associated with the medication, strict FDA approval norms and other government regulations and availability of alternate treatment procedures may act as the barrier for this market. Strong pipeline drugs and consolidation opportunities in the healthcare industry will pose future growth prospect for this market.


Anti-viral drugs represent the largest market in the liver disease therapeutics, which is justified by the fact that many oral, direct-acting antiviral medications are in development phase for treating hepatitis C. Currently, anti-virals are only available for hepatitis B and C. However, many anti-viral hepatitis C pipeline drugs namely GS-7977 (Nucleoside/Nucleotide polymerase inhibitor), Daclatasvir (NS5a Inhibitor), Asunaprevir (Protease Inhibitor), Simeprevie (Protease Inhibitor), and Vaniprevir (Protease Inhibitor), are expected to accelerate this market in near future.

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html


This research is specially designed to estimate and analyze the demand for liver diseases therapeutics in global market. The research provides an in-depth analysis of the product sales, drugs class wise trend analysis and the major player pertaining to this market. High level analysis of the mentioned drug class of global liver diseases therapeutics market is performed and the report provides detailed analysis, comprehensive historical data and statistically tested forecast of the drug classes thus covered. Detailed qualitative information is given for different liver diseases and the application of different drugs as the treatment and therapy option.

Insulin Market
According to a new market report published by Transparency Market Research "Insulin Market - Global and China Scenario, Trends, Industry Analysis, Size, Share and Forecast, 2011 - 2018" the global insulin market was worth USD 12,476.3 million in 2011 and is expected to reach USD 32,346.7 million in 2018, growing at a CAGR of 12% from 2011 to 2018. In the global market, China is expected to increase its share in the global insulin market to 10.2% by 2018.
The global insulin market is driven by rise in diabetic population worldwide. The world diabetes population was estimated at 366 million in the year 2011, and is expected to reach 552 million in 2030. It is estimated that diabetes accounts for 4.6 million deaths, with cases of people dying due to lack of insulin and not even being diagnosed.

This however, presents a huge supply demand deficit for insulin, with high growth potential in developing markets. The factors contributing to the insulin market growth also includes increase in global expenditure on healthcare, strong distribution network, and high scope in developing economies such as China and India.

Browse the full Insulin Market Report at http://www.transparencymarketresearch.com/insulin-market.html

It is estimated that worldwide, by year 2030, one in ten people will suffer from diabetes, giving rise to huge demand for insulin. China, being the most populous nation in the world, accounts for the largest share of the global diabetic population and eventually turns out as the most lucrative market for insulin manufacturers.


The China insulin market is projected to grow at a CAGR twice that of the global insulin market. It was estimated at USD 723.8 million in 2011, and is projected to reach USD 3,299.1 million in the year 2018, growing at a CAGR of 24.6%. Currently, China accounts for 6.1% of the global insulin market in terms of volume, which was estimated at 22.4 tMU in 2011. The global insulin market by volume is projected to grow at a CAGR of 7.9% from 2012 - 2018.


The global insulin market has continuously witnessed new advanced product types being introduced in the market by insulin manufacturers. The recent product type is modern insulin, which is a genetically engineered version of human insulin, and has been selectively modified to counter the issues associated with human insulin. Currently, modern insulin accounts for more than 76% of the global insulin market.
To meet the rising demand, global insulin manufacturers are not only augmenting existing production facilities, but also expanding their global presence to meet the supply demand gap. Leading insulin manufacturers are now focusing on reinforcing their market leadership in China. It includes key global and China insulin market players such as Novo Nordisk, Sanofi-Aventis, and Eli-Lilly. Together they account for more than 90% of the global insulin market share.



This research is specially designed to estimate and analyze the demand and performance of the global and China insulin market in the current market scenario. This research provides in-depth analysis of insulin manufacturers, product sales, trend analysis by segments, and demand by geography. The report covers all the major product segments of the global and China insulin market and provides in-depth analysis, historical data and statistically refined forecast for the segments covered. 

Thursday, 12 June 2014

According to a new market report published by Transparency Market Research "Membrane separation Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019," the global membrane separation market was valued at USD 19.0 billion in 2012 and is expected to grow at a CAGR of 10.8% from 2013 to 2019, to reach an estimated value of USD 39.2 billion in 2019.

Browse the full Membrane separation Market Report at http://www.transparencymarketresearch.com/membrane-separation-market.html

The increasing demand for clean processed water and mandatory government regulation to provide clean drinking water is propelling the water processing industry at present. Membrane separation is one of the most popular methods used for cleaning water. Shifting from chemical to physical treatments of water is also a major driver as chemical treatments are perceived as an environmentally unclean technology with associated disposal costs. Additional awareness of water scarcity has influenced the demand for water reuse in water stressed areas. Governments and municipal authorities are increasingly waking up to the effects of environmental degradation on the economy. Mandatory adherence of certain environmental standards by the national government such as the Clean Water Act especially in areas with water scarcity have influenced the demand for better water treatment technology, including membrane separation technology.


Worldwide industrial expansion and growing population are propelling the demand for better water treatment technology, providing growth opportunity for the overall market of membrane separation technology. Additionally, the oil and petroleum industry is well established in countries such as Italy and Germany which involve membrane separation technology for liquid separation. Membrane separation technology is majorly divided under four major processes, microfiltration, ultrafiltration, nanofiltration and reverse osmosis. Microfiltration dominates the market with more than 35% global market share. Whereas water & wastewater dominates the end-user market with 36% global market shares in terms of uses. The global membrane separation market grew from USD 19.0 billion in 2010 to USD 21.2 billion in 2013.
European membrane market is expected to reach USD 13.8 billion in 2019. In 2012 water & wastewater sector was the major end-user of membrane separation technology and is expected to increase at a CAGR of 11.1% during 2013-19. The membrane separation technology market is fragmented with several players in the market supplying membrane separation to the end-users in the market.


Membrane separation is used by various sectors such as water and wastewater treatment and industrial and healthcare sectors. Most of the companies produce different types of membrane products such as microfiltration, nanofiltration, ultrafiltration and reverse osmosis and sell them globally. Major companies that are operating globally and manufacturing all four products are Koch Membrane Systems Inc., Pall Corporation, Merck Millipore, 3M Company, Degremont SA, Dow Chemical Company, GEA Filtration, Nitto Denko Corporation, Époque Water Technologies and Veolia Environnement.